Improving Skin Cancer Management With Artificial Intelligence (04.17 SMARTI)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

200 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-10-01

Study Completion Date

2021-05-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The study is designed to be able to prove if the Molemap Artificial Intelligence (AI) algorithm can be used as a diagnostic aid in a clinical setting. This study will determine whether the diagnostic accuracy of the Molemap AI algorithm is comparable to a specialist dermatologist, teledermatologist and registrar (as a surrogate for a general practitioner). The study patient population will be adult patients who require skin cancer assessment.

The use of AI as a diagnostic aid may assist primary care physicians who have variable skill in skin cancer diagnosis and lead to more appropriate referrals (rapid referral for lesions requiring treatment and fewer referrals for benign lesions), thereby improving access and reducing waiting times for specialist care.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Generation of an Artificial Intelligence Algorithm Based on the Analysis of Melanoma Peri-scar Dermatoheliosis, as a Predictive Factor of Response to Anti-PD-1

NCT05856565

Metastatic Melanoma

RECRUITING

Melanoma Surveillance Photography (MSP) to Improve Early Detection of Melanoma in Ultra-high and High Risk Patients

NCT04385732

Melanoma Skin Cancer Anxiety and Fear

ACTIVE_NOT_RECRUITING NA

Artificial Intelligence Based Melanoma Early Diagnosis and Risk Prediction in Children, Adolescents and Young Adults

NCT06621810

Melanoma (Skin Cancer) Artificial Intelligence (AI) Pediatric Cancer

RECRUITING

Melanoma Image Analysis Algorithm (MIAA) Validation Study

NCT02612168

Malignant Melanoma

COMPLETED NA

AI-Augmented Skin Cancer Diagnosis in Teledermatoscopy

NCT06080711

Skin Cancer Melanoma

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a pilot study which aims to establish whether artificial intelligence can be used as a diagnostic aid to improve diagnostic accuracy and outcomes in the specialist setting prior to conducting a much larger trial of the intervention in primary care.

Objectives:

1. To establish whether the diagnostic accuracy of an artificial intelligence system is on par with teledermatologists' clinical assessment.
2. To establish the safety and feasibility of offering artificial intelligence as a diagnostic aid prior to conducting a large trial of the intervention in primary care.

Hypotheses:

1. The AI algorithm will have diagnostic accuracy comparable with a teledermatologists' assessment.
2. The AI algorithm will have a diagnostic accuracy more conservative (i.e. more false positives) than dermatologists in the clinical setting.
3. The AI algorithm will have greater diagnostic accuracy than the registrar.
4. The AI algorithm will lead to a reduction in the number of biopsies performed by the registrar the likely impact of which will be reduced cost to patients and the healthcare system.

Trial Design:

The pilot study will take place in specialist dermatology and melanoma clinics in Victoria, Australia. Potential participants will be identified and screened at the general dermatology and melanoma clinics by the clinic doctors who deem the participant meet the inclusion and exclusion criteria.

Intervention:

Photography of lesions using a MoleMap camera device with automated artificial intelligence providing an assessment of the lesion in real time.

This pilot study will be a before and after intervention trial design. For the initial 'lead-in' phase, no AI diagnosis will be provided back to the treating clinicians. This phase will be used for prospective data collection.

For the intervention phase, an AI diagnosis will be provided to the dermatology registrar (who is used in this pilot study as a surrogate for the GP) and dermatologist after they have both assessed the patient clinically. Management of the lesion will be determined by the dermatologist and recorded.

The safety of the device will be determined by its use in the setting of specialist dermatology clinics to ensure that patients are receiving the highest standard of care with a dermatologist providing a clinical diagnosis and management for all lesions tested.

It is anticipated that the full trial will expand to include multiple sites across Australia and New Zealand.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Skin Cancer Melanoma (Skin)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SEQUENTIAL

Controlled before-and-after intervention study

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

SINGLE

Outcome Assessors

Teledermatologist will be blinded to the Artificial Intelligence algorithm diagnosis.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Lead-in phase

During the lead-in phase treating clinicians will not be given the Molemap artificial intelligence diagnosis in real-time (i.e. in clinic with the patient).

Group Type NO_INTERVENTION

No interventions assigned to this group

Active phase

During the active phase treating clinicians will be given the Molemap artificial intelligence diagnosis in real-time.

Group Type ACTIVE_COMPARATOR

Molemap Skin Cancer Triage Artificial Intelligence Device

Intervention Type DEVICE

This device/software incorporates artificial intelligence to provide a diagnostic aide for clinicians of patients with potentially malignant skin lesions. The software is supported by the use of cameras for acquisition of images.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Molemap Skin Cancer Triage Artificial Intelligence Device

This device/software incorporates artificial intelligence to provide a diagnostic aide for clinicians of patients with potentially malignant skin lesions. The software is supported by the use of cameras for acquisition of images.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Patients attending the specialist dermatology clinics for skin cancer assessment or surveillance.
2. Patients may or may not have a lesion of concern.
3. Patients must have at least two lesions imaged during full skin examination by a dermatologist.
4. Age greater than 18 years.
5. Participant is willing and able to undertake investigation of suspicious lesion (e.g. skin biopsy).

Exclusion Criteria

1. Patient does not give informed consent.
2. Patient is unable or unwilling to have a full skin examination
3. Patient has a known past or current diagnosis of cognitive impairment

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No